S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

$83.12
+3.11 (+3.89%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$79.36
$85.95
50-Day Range
$78.08
$123.34
52-Week Range
$61.58
$178.71
Volume
1.17 million shs
Average Volume
477,330 shs
Market Capitalization
$4.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86
30 days | 90 days | 365 days | Advanced Chart
Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Ascendis Pharma A/S logo

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
639
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.20 million
Book Value
$18.38 per share

Profitability

Net Income
$-453.81 million
Net Margins
-3,281.45%
Pretax Margin
-4,936.36%

Debt

Price-To-Earnings

Miscellaneous

Free Float
34,163,000
Market Cap
$4.73 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/16/2022
Next Earnings (Estimated)
8/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

312th out of 1,403 stocks

Pharmaceutical Preparations Industry

124th out of 667 stocks

Analyst Opinion: 4.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

Is Ascendis Pharma A/S a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S
or view top-rated stocks.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 24th 2022.
View our earnings forecast for Ascendis Pharma A/S
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.25) by $0.04. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 51.08% and a negative net margin of 3,281.45%. During the same period in the previous year, the firm earned ($1.41) earnings per share.
View Ascendis Pharma A/S's earnings history
.

What price target have analysts set for ASND?

11 Wall Street analysts have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their forecasts range from $117.00 to $197.00. On average, they expect Ascendis Pharma A/S's stock price to reach $163.40 in the next twelve months. This suggests a possible upside of 96.6% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Ascendis Pharma A/S's key executives?
Ascendis Pharma A/S's management team includes the following people:
  • Mr. Jan Moller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 62)
  • Mr. Michael Wolff Jensen L.L.M., Sr. VP, Chief Legal Officer & Member of the Exec. Board (Age 51)
  • Dr. Birgitte Volck M.D., Ph.D., Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs (Age 60, Pay $24.84k)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 48)
  • Ms. Lotte Sonderbjerg, Chief Admin. Officer, Sr. VP & Member of the Exec. Board (Age 61)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 53)
  • Mr. Flemming Steen Jensen, Sr. VP of Product Supply & Quality (Age 61)
  • Dr. Kennett Sprogoe, Sr. VP and Head of Innovation & Research (Age 43)
  • Dr. Juha Punnonen M.D., Ph.D., Sr. VP & Head of Oncology (Age 56)
  • Dr. Jens Sigurd Okkels Ph.D., Sr. VP of Product Devel. (Age 61)
What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (1.35%), Brown Advisory Inc. (0.88%), TimesSquare Capital Management LLC (0.88%), Sei Investments Co. (0.78%), BlackRock Inc. (0.70%) and American Century Companies Inc. (0.62%).

Which institutional investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., TimesSquare Capital Management LLC, Allianz Asset Management GmbH, Raymond James & Associates, Nan Fung Group Holdings Ltd, Henry James International Management Inc., Evolutionary Tree Capital Management LLC, and Mackenzie Financial Corp.

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Affinity Asset Advisors LLC, BlackRock Inc., Nicholas Investment Partners LP, Bank of New York Mellon Corp, Wolverine Asset Management LLC, Rice Hall James & Associates LLC, American Century Companies Inc., and Brown Advisory Inc..

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $83.12.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S has a market capitalization of $4.73 billion and generates $9.20 million in revenue each year. The biotechnology company earns $-453.81 million in net income (profit) each year or ($9.36) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S employs 639 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at (457) 022-2244, via email at [email protected], or via fax at 45-3694-4010.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.